Page last updated: 2024-12-07

l 012

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L 012: used as a chemiluminescent probe for the assay of human fibroblast growth factor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126741
SCHEMBL ID8335960
SCHEMBL ID18791869
MeSH IDM0217642

Synonyms (12)

Synonym
l 012
8-amino-5-chloro-7-phenyl-2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione
l-012
143323-55-1
pyrido(3,4-d)pyridazine-1,4-dione, 8-amino-5-chloro-2,3-dihydro-7-phenyl-
8-amino-5-chloro-2,3-dihydro-7-phenylpyrido(3,4-d)pyridazine-1,4-dione
8-amino-5-chloro-7-phenylpyrido(3,4-d)pyridazine-1,4(2h,3h)dione
SCHEMBL8335960
DTXSID30162387
SCHEMBL18791869
8-amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4(2h,3h)dione
AKOS040752290
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (15.00)18.2507
2000's7 (35.00)29.6817
2010's10 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.58 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index46.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]